WT1 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with WT1-specific TCR gene"

Trial Profile

WT1 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with WT1-specific TCR gene"

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs WT1 TCR-transduced T cells-Takara Bio (Primary) ; Montanide ISA-51
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 05 Nov 2016 Status changed from suspended to discontinued.
    • 06 May 2016 Status changed from recruiting to suspended.
    • 07 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top